The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo
Publications
Renal tuberculosis in an imatinib-treated chronic myeloid leukemia.
Jornal brasileiro de nefrologia. 2020;42(3):366-369
Tuberculous and non-tuberculous granulomatous lymphadenitis in patients receiving imatinib mesylate (glivec) for metastatic gastrointestinal stromal tumor.
Case reports in oncology. 2013;6(1):134-42
Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia.
The European respiratory journal. 2009;33(3):670-2